Key Action Statement Profile: KAS 4B
| Aggregate evidence quality | Grade C |
| Benefits | Successful treatment of β-lactamase–producing organisms. |
| Risks, harms, cost | Cost of antibiotic. Increased adverse effects. |
| Benefits-harms assessment | Preponderance of benefit. |
| Value judgments | Efficacy is more important than taste. |
| Intentional vagueness | None. |
| Role of patient preferences | Concern regarding side effects and taste. |
| Exclusions | Patients with known penicillin allergy. |
| Strength | Recommendation |
| Aggregate evidence quality | Grade C |
| Benefits | Successful treatment of β-lactamase–producing organisms. |
| Risks, harms, cost | Cost of antibiotic. Increased adverse effects. |
| Benefits-harms assessment | Preponderance of benefit. |
| Value judgments | Efficacy is more important than taste. |
| Intentional vagueness | None. |
| Role of patient preferences | Concern regarding side effects and taste. |
| Exclusions | Patients with known penicillin allergy. |
| Strength | Recommendation |